Loading
A phase 2 trial of Serplulimab in hepatocellular carcinoma, run by Shanghai Henlius Biotech, now recruiting.
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. is a phase 2 interventional study registered as NCT06349980 by Shanghai Henlius Biotech, with 117 participants planned, started 2024-08-05 and due to reach its primary completion in 2027-02-10. Interventions recorded: HLX53 (1000mg), HLX53 (2000mg), HLX10 and HLX04.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Henlius Biotech, Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/